$4.5m raised
$5m won in prizes & grants
Winner of Elon Musk’s XPRIZE 2021
Winner of Shell New Energy Challenge 2023
Winner of L'Oreal GSI 2024
Winner of Horizon Europe 2024
About
The future of resilient biomanufacturing.
Since 1978, Pharma companies have been inserting genes into cells to make >170 biological drugs that are too complex to make with chemistry. The technique is predisposed to enormous supply risks compounded by contamination issues, over-dependence on critical input materials and a high barrier for market competition.
In 2023, over 27% of essential medicines and 54% of pharmaceutical supply were classified by the DLA as “very high risk” due to reliance on unknown supply origins. In the last two years, six insulin products were discontinued - resulting in shortages globally.
METRICS
$40 bn
Total market size of products synthesised at cost parity or less
200+
GMO strains engineered
3/7
Biological products in the pipeline successfully synthesised from platform
2
Private contracts delivered
$27m
Pre-orders & LOIs
De-risking critical supply chains
Scaling additional capacity faster.
CyanoCapture enables users to synthesise $40bn market's worth of high value biomolecules cheaper from anywhere, without Precision Fermentation systems. The platform uses CO2 + light instead of sugars, thereby requiring significantly less complex equipment and facilities.
Step 1
The 'Rolls-Royce engine'
A patented record-breaking photoautotroph. Robust. Scalable. Doubles every 2 hours.
This is the chassis on which all our production is built.
Step 2
Reprogramming biology
We turn the chassis into a powerful molecular factory - secreting valuable molecules synthesised from inorganic media containing CO2, nitrates and phosphates. No chemical energy is required. Creating a protective environment against heterotrophic contamination.
Two years of intense development produced patented cloning methods, CRISPR and a proprietary library of genetic parts and unique methods. CyanoCapture has quietly engineered 200+ strains with unparalleled degrees of freedom.
Step 3
Self-reliant plug-and-play systems
These cells are loaded into low-cost Photobioreactor (PBR) systems that integrate at CDMO facilities, replacing costly GMP Precision Fermentation systems.
The cells are capable of self-repair and self-replication.
Step 4
Unlocking domestic distributed manufacturing: Same COGS achievable at an order of magnitude smaller scale
$40+ billion worth of high-value compounds can be synthesised using a category-defining manufacturing process.
How it works
Our Core Technology
Leveraging proprietary multi-omics datasets and ML to gain unparalleled control of the world's fastest light-powered cellular factory.
Industrial Enzymes
Peptides
Commodity chemicals
Bioplastics
Growth factors
Cytokines
Serum-free media
Targeted drug delivery (Protein shell nanocages)
A broad platform, ready for the future bioeconomy.
Case Study
A $30bn market drug molecule - breakthrough
Though this drug is currently manufactured already by genetically engineered microbes, so far no one has been able to power this process without using chemical energy. We are the first company globally to successfully synthesise this molecule using a zero-sugar process.
Working at scale.
Modular • Profitable • Scalable • Low-Energy • Biological Precision •
Products
IFN-Alpha
Peptide drug X
2x more Pharmaceutical products in pipeline (to be announced soon)
3750L Non-Pharma grade biomanufacturing (Canada)
2500L CDMO project (India)
kg/month scale production from January 2026. Please enquire about product offtakes.
Q1 2026
Now offering fixed supply agreements with 30%
cheaper than market price guaranteed for first 50 companies.
New website launching soon
